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Conclusion  
For realistic dose distributions and cohort sizes, a state-
of-the-art analysis failed to identify the postulated dose-
response in about 2-in-3 cases for the low incidence of the 
large-volume effect complication radiation pneumonitis. 
Very large patient cohorts were required to ensure 
recognition rates above 90%. This fundamentally low 
success rate could explain the persistent difficulties to 
derive dose constraints from clinical data for 
complications in large-volume effect, “parallel” organs. 
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Purpose or Objective  
Radiotherapy is a standard treatment modality with 
curative intent for localized prostate cancer. Prostate 
cancer is a disease of elderly men. Nevertheless these 
patients have a remaining life span of ten years or more. 
Radiotherapy compared to surgery may increase the risk 
for second cancer. Minimizing this risk can be one criterion 
in deciding for a specific technique.  Therefore we 
compared the organ equivalent dose (OED) and excess 
absolute risk (EAR) for second cancer for different 
treatment techniques.  
Material and Methods  
For ten patients four different plans were calculated, 
using a seven field intensity modulated radiotherapy 
(IMRT) and a single arc volumetric modulated arc therapy 
(VMAT) with and without flattening filter. The 
optimization was performed as simultaneous integrated 
boost in 33 fractions, aiming for 59.4 Gy minimum dose to 
the PTV and 71.0 Gy minimum dose and 74.2 Gy maximum 
dose to the CTV. The OED was computed for the urinary 
bladder and the rectum from dose volume histograms for 
the linear-exponential (LEM) and the plateau dose-
response model (PM). The EAR can be derived from the 
OED, taking age modifying parameters into account. The 
statistical analysis was performed using the Wilcoxon test 
in IBM® SPSS® Statistics 23 (IBM Corporation). 
Results  
Within one technique (IMRT or VMAT) the average value of 
the OED is lower for the flattening filter free (FFF) mode 
compared to flat beams (FB) in both organs and for both 
dose-response models with one exception: In the urinary 
bladder it is the other way round for IMRT and the LEM 
These results are statistically significant (level of 
significance 5%). The results for VMAT are statistically 
significant for the rectum only in both models. 
Comparing IMRT and VMAT the results are ambiguous:  For 
the LEM the OED is lower with IMRT for both FB and FFF, 
for the PM lower OEDs are achieved with VMAT.  All results 
are significant, except of one (LEM, FFF, urinary bladder, 
p = 7.4%). 
The average values for the EAR for patients of 71 years at 
exposure and an attained age of 84 years are given in table 
1.
 
Conclusion  
Some statistically significant differences have been found 
for the different treatment techniques and modes. 
However, they depend on the dose-response model. For 
the PM the lowest EAR is found for VMAT FFF in both organs 
at risk, for the LEM IMRT FB shows the minimum values. 
Plan quality and efficiency should additionally be regarded 
before the decision for a specific technique and mode.  
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Purpose or Objective  
To present the preliminary results of the prospective 
phase II trial of a novel device, called DIFGI, for deep 
inspiration breathhold (DIBH) in left-sided breast cancer. 
We will focus on the performance of the device as well as 
on the dosimetrical benefits of the technique. 
Material and Methods  
DIFGI is a simple, friendly, low-priced  external 
respiration-monitoring device developed in our institution 
that has obtained a utility model protection (Fig.1). The 
patients hold her breath in supine position until contacting 
an horizontal bar, which activates an acoustic and a visual 
signal that offers feedback to the patient and the RTTs, 
